Holders — by stockHoldings — by fund
NOVO HOLDINGS A/S
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 1388325
$1.72B
disclosed book value
25
positions
12.6%
largest position share
Positions, as of 2026-06-30
top 25 of 25 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | EWTXEDGEWISE THERAPEUTICS INC | 5.3M | $217.4M | 12.6% |
| 2 | ASML HOLDING N V | 94,946 | $188.9M | 11% |
| 3 | COAGHEMAB THERAPEUTICS HLDGS INC | 4.2M | $153.6M | 8.9% |
| 4 | BNBROOKFIELD CORP | 3.5M | $149.5M | 8.7% |
| 5 | MPLTMAPLIGHT THERAPEUTICS INC | 3.7M | $132.1M | 7.7% |
| 6 | MIRMMIRUM PHARMACEUTICALS INC | 1.1M | $131.7M | 7.6% |
| 7 | AVLNAVALYN PHARMACEUTICALS INC | 3.9M | $127.8M | 7.4% |
| 8 | CRMSALESFORCE INC | 393,187 | $61.6M | 3.6% |
| 9 | AVBPARRIVENT BIOPHARMA INC | 1.5M | $52.1M | 3% |
| 10 | ELVNENLIVEN THERAPEUTICS INC | 1.0M | $50.8M | 2.9% |
| 11 | CRNXCRINETICS PHARMACEUTICALS IN | 1.3M | $49.4M | 2.9% |
| 12 | PHARVARIS N V | 1.4M | $48.4M | 2.8% |
| 13 | FNDFLOOR & DECOR HLDGS INC | 797,000 | $47.3M | 2.7% |
| 14 | PCVXVAXCYTE INC | 800,000 | $46.5M | 2.7% |
| 15 | FDMT4D MOLECULAR THERAPEUTICS IN | 3.2M | $43.2M | 2.5% |
| 16 | VRDNVIRIDIAN THERAPEUTICS INC | 2.1M | $39.2M | 2.3% |
| 17 | CLDXCELLDEX THERAPEUTICS INC NEW | 1.0M | $38.1M | 2.2% |
| 18 | ALMSALUMIS INC | 1.1M | $31.0M | 1.8% |
| 19 | XENEXENON PHARMACEUTICALS INC | 485,438 | $29.3M | 1.7% |
| 20 | BABAALIBABA GROUP HLDG LTD | 257,327 | $24.7M | 1.4% |
| 21 | DYNDYNE THERAPEUTICS INC | 960,394 | $21.3M | 1.2% |
| 22 | BBOTBRIDGEBIO ONCOLOGY THERAPEUT | 2.3M | $17.1M | 1% |
| 23 | INSMINSMED INC | 120,723 | $12.9M | 0.7% |
| 24 | MARQETA INC | 441,558 | $7.2M | 0.4% |
| 25 | LNZALANZATECH GLOBAL INC | 158,148 | $1.1M | 0.1% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.